Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Shares Outstanding (Diluted Average) (2021 - 2025)

Verrica Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $10.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $10.7 million for Q4 2025, up 105.61% from a year ago — trailing twelve months through Dec 2025 was $10.7 million (up 105.61% YoY), and the annual figure for FY2025 was $10.7 million, up 105.61%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $10.7 million at Verrica Pharmaceuticals, up from $9.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for VRCA hit a ceiling of $94.8 million in Q1 2025 and a floor of $4.7 million in Q2 2024.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $27.5 million (2022), compared with a mean of $29.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 89.87% in 2024 and later soared 105.61% in 2025.
  • Verrica Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $27.0 million in 2021, then grew by 26.32% to $34.2 million in 2022, then surged by 32.72% to $45.3 million in 2023, then crashed by 88.57% to $5.2 million in 2024, then soared by 105.61% to $10.7 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $10.7 million (Q4 2025), $9.5 million (Q3 2025), and $9.5 million (Q2 2025) per Business Quant data.